Scarica l'app Stockscreener
0.99
0.22%
0.0022
Dopo l'orario di chiusura:
1.01
0.02
+2.02%
Precedente Chiudi:
$0.9878
Aprire:
$1.0122
Volume 24 ore:
24,744
Relative Volume:
0.25
Capitalizzazione di mercato:
$20.96M
Reddito:
$128.60K
Utile/perdita netta:
$-4.60M
Rapporto P/E:
-1.5714
EPS:
-0.63
Flusso di cassa netto:
$-3.74M
1 W Prestazione:
-6.60%
1M Prestazione:
-16.81%
6M Prestazione:
-64.13%
1 anno Prestazione:
-40.36%
Intervallo 1D:
$0.99
$1.0369
Intervallo di 1 settimana:
$0.89
$1.06
Portata 52W:
$0.591
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
Nome
Nexalin Technology Inc
Settore
Industria
Telefono
(832) 260-0222
Indirizzo
1776 YORKTOWN, HOUSTON
Confronta NXL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.99 | 20.96M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
136.26 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.78 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.74 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.75 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.18 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Nexalin Technology Inc Borsa (NXL) Ultime notizie
Jane Street Group LLC Buys New Position in Nexalin Technology, Inc. (NASDAQ:NXL) - Defense World
Nexalin Technology closes partial over-allotment option By Investing.com - Investing.com Nigeria
Nexalin Technology closes partial over-allotment option - Investing.com
Nexalin Technology Closes Additional Share Offering - TipRanks
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment - mx.advfn.com
Northern Trust Corp Makes New Investment in Nexalin Technology, Inc. (NASDAQ:NXL) - Defense World
Nexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - IndyStar
Nexalin Technology, Inc.: Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3 - GlobeNewswire
Nexalin Technology, Inc. to Host Investor Webinar Showcasing Innovative Neurostimulation Advances on June 3, 2025 - Nasdaq
Revolutionary Mental Health Tech: Nexalin Unveils Game-Changing Treatment in $537B Market Webinar - Stock Titan
Coming This Week: Get Ready for the ‘Last Wave of Negative News’ on Nvidia Stock - The Globe and Mail
Is This Dependable Growth Stock a Buy Right Now? - The Globe and Mail
Integrated Cyber Solutions Joins NVIDIA Connect Program to Accelerate Development of AI-Driven IC360 Cybersecurity Platform - The Globe and Mail
Clarifai Wins 2025 AI TechAward for Compute Orchestration - The Globe and Mail
Nexalin Technology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Nexalin Technology (NASDAQ:NXL) Shares Up 1.7% – Here’s Why - Defense World
Nexalin Technology slides after pricing $5M stock offering - MSN
Comparing Gadsden Properties (OTCMKTS:GADS) & Nexalin Technology (NASDAQ:NXL) - Defense World
Nexalin Technology Forms Scientific Advisory Board - citybiz
Nexalin Technology (NXL) Enhances Scientific Advisory Board to T - GuruFocus
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data - The Manila Times
Nexalin Technology Reconstitutes Scientific Advisory Board - GlobeNewswire
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data - Stock Titan
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - Taiwan News
Nexalin Technology, Inc. Closes Public Offering of 3,850,000 Shares at $1.30 Per Share, Raising $5.0 Million - Nasdaq
Brain Tech Pioneer Nexalin Secures $5M Funding: 3.85M Shares at $1.30 in Public Offering - Stock Titan
Nexalin Technology Announces Public Offering Agreement - TipRanks
Form 424B4 Nexalin Technology, Inc. - StreetInsider
Nexalin Gains International Traction - ACCESS Newswire
Nexalin Shares Fall After Pricing of $5 Million Public Offering - marketscreener.com
Nexalin Technology (NXL) Announces Public Stock Offering | NXL S - GuruFocus
Nexalin Technology sets public offering at $1.30 per share - Investing.com Australia
Nexalin Prices 3.85 Mln Public Offering At $1.30/shr; Stock Plunges In Pre-market - Nasdaq
Nexalin Technology sets public offering at $1.30 per share By Investing.com - Investing.com India
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewswire
Nexalin Technology Prices $5 Million Public Offering - marketscreener.com
$5M Public Offering: How Nexalin Plans to Advance Revolutionary Brain Stimulation Technology - Stock Titan
SEC Form 424B5 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology, Inc. (NASDAQ:NXL) Shares Acquired by Geode Capital Management LLC - Defense World
SEC Form 424B4 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology (NXL) Seeks FDA Feedback for Gen-2 SYNC Syste - GuruFocus
Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design - marketscreener.com
Nexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive Disorders - Nasdaq
Nexalin Technology Initiates FDA Q-Submission Process for - GlobeNewswire
FDA Fast-Tracks Nexalin Gen-2 SYNC Review for Alzheimer's Treatment | NXL Stock News - Stock Titan
Nexalin Technology (NASDAQ:NXL) Shares Down 0.5% – Time to Sell? - Defense World
International Milestone for Anxiety-Insomnia Neurostim Company - Sleep Review
Nexalin Technology files $50M common stock offering - MSN
Nexalin Technology (NXL) Gains Approval for Clinical Trial in Br - GuruFocus
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewswire
Nexalin Technology Inc Azioni (NXL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nexalin Technology Inc Azioni (NXL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
3.10 |
1,000 |
3,100 |
155,793 |
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
2.98 |
1,000 |
2,980 |
154,793 |
| Owens David | Chief Medical Officer |
Jan 28 '25 |
Buy |
2.70 |
1,500 |
4,050 |
153,793 |
| Owens David | Chief Medical Officer |
Jan 13 '25 |
Buy |
2.50 |
2,000 |
5,000 |
151,293 |
| Owens David | Chief Medical Officer |
Jan 23 '25 |
Buy |
2.70 |
1,000 |
2,700 |
152,293 |
| Owens David | Chief Medical Officer |
Oct 28 '24 |
Buy |
2.19 |
500 |
1,095 |
148,293 |
| Owens David | Chief Medical Officer |
Aug 13 '24 |
Buy |
0.95 |
1,000 |
950 |
147,793 |
4.52%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):